Advanced Cancer Therapeutics Enters Phase 1 Human Clinical Trials With First-in-Class Anti-Cancer Drug Candidate
6/4/2014 9:05:45 AM
LOUISVILLE, Ky., June 4, 2014 (GLOBE NEWSWIRE) -- Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, announced today that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials. The U.S. Food and Drug Administration (FDA) approved Phase 1 dose escalation study is evaluating the safety, tolerability and anti-tumor activity of PFK-158 in cancer patients with solid tumors such as melanoma, lung, colon, breast and pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by